Brief: Nymox announces prostate cancer clinical trial results from completed 18 month endpoint study
09/02/2016 15:00
Feb 9 (Reuters) - Nymox Pharmaceutical Corp NYMX.O : * Announces prostate cancer clinical trial results from completed 18 month endpoint study * Says the study successfully met its pre-determined endpoints * Says cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups * Source text for Eikon ID:nGNXMMGWFa * Further company coverage NYMX.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Nymox Pharmaceutical
See all newsBrief: Nymox Says Required To Resubmit Application To DKMA
Brief: Nymox Pharmaceutical Corp Says Terminated Employment Of Christopher R Riley As CFO (June 27)
Brief: Nymox Announces Appointment Of Christopher R. Riley As Chief Financial Officer
Brief: Nymox Appeals Deficiency Letter
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba